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ABSTRACT 
 
 
 
The purpose of this project was to generate a mouse line containing a heart-specific 
deletion of genes encoding JNK-1 and -2, which may map to insulin-resistance, to create a model 
for studying the effects of type II diabetes on cardiomyocytes.  The Cre/loxP recombination 
system was used in a C57BL/6 mouse, with Cre under the control of a MHC promoter to drive 
expression in cardiomyocytes.  PCR analysis showed the creation of 3 Cre-positive mice for 
JNK1, and 3 for JNK2, providing mice which can be used to determine the potential role of 
JNK1 and JNK2 in insulin-resistance in heart cells. 
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BACKGROUND 
 
Diabetes 
Overview 
Diabetes originates from the term Diabetes Mellitus; diabetes is a Greek word which 
means to siphon, referring to one of the most obvious symptoms of the disease, excessive 
urination.  Mellitus is Latin, meaning “sweet like honey”, and refers to an anonymous physician 
who upon tasting the urine of a diabetic concluded it had a sweet taste (Lundstrom and Rossini, 
2004). Diabetes affects nearly 300 million people worldwide and is one of the leading causes of 
death in the most developed countries (Diabetes Atlas 2011). Diabetes is a disease resulting in 
glucose dys-regulation from a set of failures in metabolism relating to insulin and the cellular 
uptake of glucose.  
 
General Description 
Diabetes is a chronic disease in which the human system fails to maintain glucose 
homeostasis, resulting in high blood sugar levels from an absence or deficiency of insulin in the 
system, or an inability of the body to respond to it.  Insulin is the main hormone that stimulates 
the conversion of sugar obtained from food into energy.  In the absence or deficiency of this 
hormone (Type I diabetes, discussed below), glucose is unable to enter essential target tissues, 
resulting in hyperglycemia.  When serum glucose levels increase, there is a flight or fight 
response by the body causing symptoms such as nausea and jitters (Marieb, 2002).  During this 
fight or flight response, the body makes excess glucose to prepare for survival, and this excess 
glucose is expelled by urination from the body in a process called glycosuria (Marieb, 2002). 
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As a result of decreased insulin, there is a deficiency of cellular sugars needed for 
metabolism. Hence, fat production is activated to provide energy, and this state of very high 
levels of fatty acids is known as lipidemia (Marieb, 2002).  The products of fat metabolism are 
known as ketone bodies, and they are very strong organic acids.  The accumulation of these 
compounds in the serum leads to their excretion in the urine.  In severe cases, known as 
ketonuria, it leads to a drop in the blood pH.  This in turn leads to an occurrence known as 
ketoacidosis.  Prolonged cases can be fatal as the low pH disturbs heart activity, transport of 
oxygen, and functioning of the nervous system  (Marieb, 2002).  
            If left untreated or undiagnosed, hyperglycemia has complications that affect every organ 
in the body (Staff, 2012).  The three main signs of diabetes are polyuria, polydipsia, and 
polyphagia. Polyuria (increased urine) results when the body reacts to excessive serum glucose 
in the kidneys (Marieb, 2002).  As a result of polyuria, there is also a large loss of ketones and 
electrolytes in the urine, causing an electrolytic imbalance. This leads to Polydipsia (excessive 
thirst) from a dehydration of the hypothalamic thirst centers, and to Polyphagia (excessive 
hunger) (Marieb, 2002).  
 
Main Types of Diabetes 
Type I Diabetes Mellitus (TID)  
There are two major forms of diabetes mellitus: type I and type II.  Type I diabetes, also 
known as Insulin-dependent diabetes mellitus (IDDM), formerly called juvenile onset diabetes, 
which usually occurs before the age of fifteen (Marieb, 2002).  Type I results when the 
pancreatic β-cells of the Islets of Langerhans that generate insulin are destroyed by the body’s 
immune system, so the body cannot produce insulin. Insulin normally binds to insulin receptors 
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on the surface of cells to upregulate signal transduction pathways that increase the presence of 
glucose transporters (GLUT) on the cell surface.  The GLUTs bind glucose releasing it in the 
cytoplasm, lowering serum glucose levels (Figure-1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Diagram of Insulin-Mediated Glucose Uptake.  Serum insulin 
binds to the insulin receptors on the cell surface to induce a signal transduction 
cascade which upregulates GLUTs on the cell surface to transport glucose into 
the cytoplasm (Beta Cell Biology, 2012). 
 
 The cause of Type I diabetes remains unknown, but some factors such as genetics, the 
status of the immune system, and the environment, can affect susceptibility (Lundstrom and 
Rossini, 2004).  Although less than 20% of the cases of IDDM have family history, there are 
some forms with familial correlations. For instance, if one of the parents has this form of Type I, 
there is a 7% chance that the child will also contract it.  With identical twins, there is a 30-50% 
chance if one has it the other will too (Lundstrom and Rossini, 2004).  Environmental factors and 
viruses such as Rubella, mumps and Coxsackie virus, are also associated with Type I.  IDDM 
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can also develop when the immune system is misdirected to attack its own β-cells (Figure-2) 
(Lundstrom and Rossini, 2004). 
 In addition to the main symptoms of diabetes discussed above (polyuria, polydipsia, and 
polyphagia), other the symptoms of Type I include significant and sudden weight loss, slow-
healing wounds, recurrent infections, and blurred vision (Diabetes Atlas, 2011).   
                                                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: The Autoimmune Response in Type I Diabetes. As a result of either 
genetic or environmental factors, auto antigens in β-cells are recognized by the 
body’s cytotoxic T cells which cause β-cell destruction (Roche Diagnostics, 
2012). 
 
Type II Diabetes Mellitus (NIDM) 
               The more common form of diabetes is known as non-insulin-dependent diabetes 
mellitus (Type II), and usually occurs in individuals after the age of 40; hence it was formerly 
regarded as adult-onset diabetes (Marieb, 2002).  However, there is recently an increase in Type 
II cases in children and adolescents.  Type II results from an increased resistance to insulin; the 
β-cells still produce insulin, but the cell does not respond to the insulin; the signal transduction 
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pathways become de-sensitized and do not upregulate GLUT (Figure-3) (Marieb, 2002). Due to 
the lack of sensitivity to insulin, and lack of GLUT upregulation, there is a build-up of glucose in 
the blood (Lundstrom and Rossini, 2004). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3:  Mechanism of Insulin Resistance in Type II Diabetes.  Prolonged 
cell stress or unknown factors lead to a desensitization of the insulin and GLUT 
pathways, so GLUT is not increased on the cell surface and glucose is not 
internalized. (dtc.ucsf.edu) 
                 
            Individuals with Type II may not be aware of their disease for a long period because the 
damage caused to the body by excess blood glucose may take a while to surface.  Diagnosis is 
usually made only after complications become evident (Diabetes Atlas, 2012).  Type II can be 
caused by stressors such as pregnancy, excessive weight gain, specific prescription drugs, or 
other illnesses. However, some factors that may lead to insulin resistance are hereditary 
(Lundstrom and Rossini, 2004).  Some Type II risk factors include obesity, poor diet, physical 
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inactivity which leads to premature aging, a genetic history of the disease, ethnicity and poor 
nutrition during pregnancy which affects the embryo (Diabetes Atlas, 2012). 
 
Prevalence 
Diabetes affects close to 300 million people worldwide and is one of the leading causes 
of death in the world’s most developed countries (Diabetes Atlas, 2011).  It is estimated that 366 
million people have developed diabetes in 2012 (Figure-4), and this number will rise by almost 
50 percent in the next 20 years.  About 10 percent of the population of the United States is 
affected by diabetes, and about 3 percent of these are unaware they have it (Diabetes Atlas, 
2011).  Diabetes complications consume about 15% of the U.S. health care budget, which is at 
least 465 billion dollars (Diabetes Atlas, 2011).  Diabetes is the leading cause of non-traumatic 
amputations, end-stage renal diseases, and increased morbidity via cardiovascular disease 
(Cavellerano, 2005).  In 2004, about four people suffered diabetic amputations daily in Louisiana 
alone (Webster, 2005). Diabetes caused 4.6 million deaths in 2011 (Diabetes Atlas, 2011).  
Diabetes is also the leading cause of blindness, and patients are 25% more likely to become blind 
than their non-diabetic counterparts (Cavellerano, 2005). Diabetes is undoubtedly one of the 
most challenging health problems of the 21st century. 
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Figure-4: Prevalence Estimates of Diabetes by 2025.  The darker the shade of 
yellow, the higher the prevalence estimate. (globalsherpa.org) 
 
Treatment 
        Type I diabetes is chronic and lifelong, hence a lot of time and money is dedicated to 
treatment. The most common and effective treatment is insulin replacement therapy.  An ideal 
form of therapy would be to implant a system capable of producing insulin as the pancreas 
normally does, however, this has yet to be perfected and has only been successfully achieved in 
mouse models.  In insulin replacement therapy, subcutaneous injections of insulin, or insulin 
pumps, are used to increase serum insulin following a meal. The insulin is biomanufactured with 
the use of recombinant DNA technology from E. coli bacteria (Lidstone, 2005).  
         In type II diabetes, the body already produces insulin, so its treatment does not usually 
involve insulin injections.  However, insulin may be prescribed in conjunction with exercise, 
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good diet, and other oral medications to form an adequate management technique (Marieb, 
2002). 
New research from Gray and Kim (2011) at the University of Massachusetts Medical 
School looks to investigate the impact of insulin-resistance on the diabetic heart. According to 
their findings, structural, metabolic, and cellular disorders can arise in the diabetic heart from 
type II diabetes.  Structurally, Type II has been shown to damage the left ventricular wall of the 
heart, specifically through the thickening of the existing present cardiac tissue in the area. And 
metabolic changes have been documented in the heart, such as increased lipid oxidation and the 
accumulation of triglycerides in the myocardium of the heart. Cellular changes in the diabetic 
heart have been also shown to occur, including mitochondrial dysfunction by the increased 
uptake of lipid fatty acids, promoting the generation of reactive oxygen species.  
 
The Cre Recombinase System for Mouse Knockouts 
Cre recombinase is a protein about 38 kDa long, originally obtained from bacteriophage 
P1, which serves as a mediator for intramolecular and intermolecular site specific recombination 
between two or more loxP sites.  When a particular gene is flanked by loxP sites (floxed), the 
binding of Cre recombinase to the sites results in an excision of the DNA intervening between 
them, which is subsequently ligated to leave one of the loxP sites behind.  The system can be 
used to eliminate any particular gene that is floxed, so long as cre is expressed in that tissue.  The 
Cre/loxP system is usually used to knock out normal chromosomal genes, but it can also be used 
to remove a transgene that has been overexpressed in specific tissues to study the effect of the 
downregulation.   
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One useful application of the Cre/loxP system involves two mouse strains bred to 
produce a deletion (Figure-5).  One transgenic mouse line containing Cre targeted to a specific 
tissue is bred with another mouse that containing the floxed target gene. Recombination and 
knockout occurs in all the cells expressing Cre, while the target gene remains active in the cells 
and tissues that do not express Cre.  The excising capability of Cre can also be useful in 
conditionally turning on foreign genes by removing stop sequences between the promoters and 
coding region of the transgene.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: The Cre/loxP Recombination System in Transgenic Mice.  One 
mouse strain expresses Cre recombinase (left) while the other strain contains the 
floxed target gene (right). Depending on the promoter used to drive the 
expression of the Cre, the offspring will express Cre in only a specific tissue, 
which will contain the knockout.  (mammary.nih.gov).  
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In diabetes research, the Cre/loxP system has already proven useful for studying insulin 
resistance in specific tissues by knocking out the insulin receptor gene in a specific tissue to 
induce a cellular hypoglycemic state in that tissue.  If expression of the Cre recombinase is 
driven by the muscle creatine kinase (MCK) promoter, the cre is expressed in skeletal muscle 
and cardiomyocytes.  If the Cre is driven by the myosin heavy chain (MHC) promoter, the Cre is 
expressed mostly in cardiomyocytes.  The “MHC-Cre mouse” has been used to study the effects 
of loss of the insulin receptor gene in mouse cardiomyocytes (Wagner, 1998), but has not yet 
been used to study the effects of deleting signal transduction genes related to insulin-resistance, 
such as JNK1 and JNK2, in the heart (see below). 
 
MAPK/JNK Pathway 
Mitogen-Activated Protein Kinases (MAPKs) are kinases activated as a result of 
extracellular stimuli.  MAPKs are expressed in various cell types, including cardiomyocytes, 
vascular endothelial cells and vascular smooth muscle cells.  c-Jun NH(2)-terminal protein 
kinases (JNKs), a type of MAPK, and are highly stimulated by environmental stresses and can be 
moderately stimulated by mitogens, inflammatory cytokines, oncogenes, and inducers of cell 
differentiation and morphogenesis (SABiosciences, 2010).  All ten of the known JNK isoforms 
identified are encoded by three genes: JNK 1, JNK 2 and JNK 3.  These JNK isoforms are very 
important in regulating stress responses, neural development, inflammation, and apoptosis 
(SABiosciences, 2010). 
 The most powerful inducers of JNK are stress or genotoxic agents. These forms of stress 
serve to mediate JNK activation via cellular pathways.  Growth factors also initiate JNK 
activation, however the pathway that leads to this activation is not fully known. The 
MAPK/JNK-stress pathway is linked to various pathological conditions, including Type II 
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diabetes and insulin resistance (Figure-6), therefore a proper understanding of this pathway 
could lead to potential therapeutic intervention and manipulation methods of these diseases 
(SABiosciences, 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: The MAPK-JNK Pathway is a Crucial Mediator of Insulin-Resistance in Type II 
Diabetes.  MAPKs are a family or serine-threonine protein kinases that participate in a major 
signaling system by which cells transduce extracellular stimuli into intracellular responses. Both 
JNK1 and JNK 2 protein kinases have been shown to be involved in obesity-related metabolic 
regulation and insulin resistance (SABiosciences, 2010). 
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PROJECT PURPOSE 
 
JNK1 and JNK2 are kinases that function in the MAPK proinflammatory pathway, and 
are important for mediating cellular stress and insulin-resistance in Type II diabetes.  In this 
project, the JNK1 and JNK2 genes will be deleted in mouse cardiomyocytes through the use of 
the MHC-Cre/LoxP recombination system.  In this system, in one strain of mice the Cre 
recombinase is driven by the myosin heavy chain (MHC) promoter which drives Cre expression 
in cardiomyocytes.  This strain is bred to another strain in which the JNK1 and JNK2 genes have 
been floxed to support their removal.  The F1 progeny will be heterozygous floxed for the JNK1 
or JNK2 allele, and either Cre-positive or Cre-negative.  Inter-crossing of the F1 progeny will 
produce F2 mice that are homozygous floxed for JNK1 or JNK2, and Cre-positive or negative 
(the latter must be determined by genotyping). 
This analysis will help determine whether the use of cell-specific genetic recombination 
in transgenic mice is a viable method for studying signal transduction components in Type II 
diabetes in specific tissues.  Following the mouse breeding, DNA will be isolated from the mice 
and genotyped by PCR to determine the status of the JNK1, JNK2, and Cre genes.  The percent 
of Cre positive mice will then be determined to facilitate subsequent experimental designs.  This 
mouse model can be used to investigate insulin-resistance and pro-inflammatory MAPK pathway 
contributions to Type II diabetes in cardiomyocytes. 
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METHODS 
 
Cre/LoxP Recombination 
In the Sauer and Henderson (1988) study, the basic parameters for performing cell-
specific gene deletion through Cre/LoxP recombination were established. Figure-7 depicts the 
general mechanism by which the target genes, in their case MAPK8 and MAPK9, were deleted.  
In this mechanism, the LoxP 34 bp nucleotide sequence, flanks or “floxes” the target gene of 
interest. Under the heart-specific promoter Myosin Heavy Chain, Cre recombinase is expressed 
in cardiomyocytes, and is able to attach to the LoxP sites in and excise the floxed target gene 
from the genome. The excised gene contains one of the LoxP nucleotide recognition sequences, 
with the other sequence remaining on the genome as a reporter gene. 
                                     
Figure 7:  Strategy for Gene Knockout:  The Outcome of the Cre-LoxP 
Recombination is Determined by the Orientations and Location of Flanking 
LoxP Sites. In this segment, the two LoxP sites are oriented in the same 
direction (cis arrangement), mediating a deletion of the floxed segment. 
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Generation of Cre-Positive Transgenic Mice 
Generation of Cre-positive, homozygous transgenic mice involved the breeding of mice 
in the F0 and F1 generation, resulting in the target progeny of the F2 generation. In the F0 
generation, male C57BL/6 mice expressing Cre recombinase under the heart specific myosin 
heavy chain (MHC) promoter were crossed with female mice containing the heterozygous floxed 
JNK1 or JNK 2 allele. The resulting F1 progeny are heterozygous floxed for the JNK1 or JNK2 
allele, and either Cre-positive or Cre-negative. For the F2 generation, heterozygous JNK1 and 
JNK2 F1 progeny were crossed to obtain homozygous floxed, Cre-positive (JNK null) mice. 
                 
 
Hot Alkaline Lysis of Mouse Tails 
 
Tail section DNA was used for genotyping.  A 0.5 mm section of each mouse tail was 
taken and mixed with 75 µL of alkaline lysis reagent. After this was done, the mouse tails were 
incubated for 30 minutes at 95°C in a dry bath to allow lysis of the tissue samples. After the dry 
bath, the specimens were cooled on ice for about 5 minutes to allow for proper DNA lysis 
optimization. Subsequently, 75 µL of neutralization reagent was added to each tube to stop the 
alkaline lysis reaction completely.  Crude DNA lysates (not phenol extracted) were obtained by 
vortexing the mixture and centrifuging the sample at 10,000 rpm for 2-3 minutes. The 
supernatant was then transferred to newly labeled tubes and stored in -20°C until PCR analysis. 
 
PCR Genotyping 
 
The purpose PCR analysis was to test for the presence of the MHC-Cre gene in F2 mice. 
This was accomplished through the use of specific 5’ and 3’ Cre-specific DNA primers. After the 
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hot alkaline mouse tail lysis had been completed, 1 µl of the purified DNA supernatant was used 
for PCR analysis. The primers used in the analysis were MHC-cre 5’: (ATG ACA GAC AGA 
TCC CTC) and MHC-cre 3’: (CTC ATC TCG TTG CAT C).  The primer triplets were used in 
amplification of genes for the F2 generation, JNK1 and JNK 2 homozygous mice. Promega 2X 
Green PCR master mix was added in a 20 µl volume to the product. The PCR Master Mix is a 
premixed, ready-to-use solution containing Taq DNA Polymerase, dNTPs, MgCl2 and reaction 
buffers at optimal concentrations for efficient amplification of DNA templates by PCR. 
Conditions for PCR analysis were 40 cycles (30 seconds at 95°C, 30 seconds at 58°C, and 30 
seconds at 72°C). 
 
Gel Electrophoresis 
Separation of the amplicon DNA in the gel was accomplished through a standard agarose 
gel electrophoresis protocol. A 1% agarose gel was used as the analysis medium and was 
prepared using a microwave heat source. After gel cooling, 5 μl of DNA marker ethidium 
bromide was added and the gel was prepared for electrophoresis using casting combs. Loading 
buffer was added to PCR/DNA solution, after which the DNA and ladder was loaded onto the 
gel, and electrophoresed at 100V for 1 hour.  Amplicons were visualized by UV trans-
illumination. 
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RESULTS 
 
 
  
 In order to generate transgenic mice with a heart-specific deletion of JNK1 and JNK2 
genes, a series of breeding procedures were followed (Figure-8).  Male mice that expressed Cre 
recombinase under a heart-specific myosin heavy chain (MHC) promoter were crossed with 
female mice containing a floxed JNK 1 or JNK 2 allele (upper part of diagram). The resultant F1 
progeny were heterozygous for floxed JNK 1 or JNK 2 alleles, and were either cre positive or cre 
negative. The F1 progeny were subsequently intercrossed, and the resultant F2 progeny were 
homogygous for floxed JNK 1 or JNK 2 alleles, and remained either cre positive or Cre negative 
(the latter state must be determined by genotyping). It is important to note that there were no 
expected significant phenotype changes in the resultant progeny. 
 
Figure 8: The Cre/loxP Mating Strategy Used in This Project.  Male mice 
expressing cre under the control of an MHC promoter were crossed with female 
mice containing floxed JIN1 or JNK2. The F1 offspring are heterozygous for 
floxed JIN1 or JIN2, and either cre positive or negative.  Interbreeding of F1’s 
produces F2’s that are homozygous for floxed JNK1 or JNK2, and either cre 
positive or negative (the latter  is determined by genotyping).  
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After producing the resultant homozygous floxed JNK1 and JNK2 F2 progeny, a hot 
alkaline lysis was performed on mouse tail sections, and a small 1 μL aliquot was used for Cre 
PCR genotyping.  The results were visualized on two agar gels, for JNK1 mice (Figure-9) and 
JNK2 mice (Figure-10).  Each gel showed the presence of the MHC-cre recombinase gene in 
three of the mice, so in total six of the mice were Cre positive.  However, one of the JNK2 
homozygous mice unexpectedly showed a shorter amplicon (lane-7 Figure-10) while one of the 
JNK1 homozygous mice showed a longer amplicon (lane-13, Figure-9).  
 
 
 
 
 
 
 
 
 
 
Figure 9: PCR Analysis for the Presence of the MHC-Cre Gene in Floxed  
JNK-1 Homozygous Mice.  MHC-Cre DNA amplified by PCR was  
visualized by agarose (1%) gel electrophoresis Each lane contained 5 µl of the  
PCR reaction. Lanes 6, 13 and 14 showed successful amplification of the MHC-
cre transgene, although the amplicon was unexpectedly longer in lane-13. 
 
Presenc
e of 
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Figure 10: PCR Analysis of the Presence of the MHC-Cre Gene in Floxed 
JNK-2 Homozygous Mice.  The legend is as described above, except the mice 
are homozygous for floxed JNK-2. Lanes 7, 18 and 19 show successful presence 
of the MHC-cre gene, however the amplicon in lane 7 is unexpectedly short. 
  
Pr
es
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DISCUSSION 
 
 
From this study, it was determined by PCR that the MHC-Cre gene was present in both 
floxed JNK1 and JNK2 homozygous mice. Amplicon signals from the MHC-Cre positive mice 
showed that the PCR design to detect the Cre gene was valid, and produced results consistent 
with the breeding experimental plan.  The results from a PCR analysis performed by other Kim 
lab personnel (data not shown) also confirm that the Cre/LoxP recombination system was 
successful in producing a heart-specific deletion on the JNK1 and JNK2 gene in the experimental 
mice.  
During this project, several problems were encountered.  One of the main problems was 
the existence of unexpected amplicon lengths in two of our MHC-Cre positive mice. It was 
concluded that the unexpected amplicon lengths likely result from a mutation in the Cre DNA 
during the PCR process. This random mutation through the addition or deletion of nucleotides 
from the target amplified DNA fragment could have caused the unexpectedly longer amplicon in 
a MHC-Cre positive JNK1 mouse, as well as an unexpectedly shorter amplicon in a MHC-Cre 
positive JNK2 mouse. The use of known Cre positive DNA could have been used to show the 
reliability of the alkaline lysis and PCR method for genotyping.  
The project was successful in detecting MHC-Cre in the F2 generation of our transgenic 
mice.  However, several questions were still left unanswered by our research. Our experiment 
used a Myosin Heavy Chain (MHC) promoter to direct cardiac tissue-specific expression of the 
Cre, and thus tissue-specific knockouts of the JNK1 and JNK2 genes using the Cre/LoxP 
method.  However, we did not use RT-PCR to verify tissue-specific expression of the Cre.  Our 
experimental PCR protocol from mouse-tail samples was designed only to determine the 
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presence of the Cre gene in the genome to distinguish Cre positive from Cre negative mice.  The 
MHC promoter has long been used in research to drive expression in cardiomyocytes (reviewed 
in Wagner, 1998), so it is logical to assume that our six Cre positive mice are expressing Cre in 
cardiomyocytes, but we did not perform RT-PCR.   
Future studies can use the mice to determine whether JNK1 and JNK2 KO mice, missing 
these key components of the MAPK pathway related to cell stress, show phenotypes for 
inflammation and insulin-resistance in cardiomyocytes.  Other studies could knockout other 
members of the MAPK pathway to determine whether they are important for mediating cell 
stress in cardiomyocytes.  While the MAPK/JNK pathway has been shown to be one of many 
pathways that stimulate Type II diabetes, its effect in this process is not well understood, mostly 
due to the complexity involved in the signaling process. Research should be done to investigate 
the specific signal that obesity uses to activate the MAPK/JNK pathway and how this could be 
stopped.  
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